OA13038A - Pryridyloxymethyl and benzisoxazole azabicyclic derivatives. - Google Patents

Pryridyloxymethyl and benzisoxazole azabicyclic derivatives. Download PDF

Info

Publication number
OA13038A
OA13038A OA1200500259A OA1200500259A OA13038A OA 13038 A OA13038 A OA 13038A OA 1200500259 A OA1200500259 A OA 1200500259A OA 1200500259 A OA1200500259 A OA 1200500259A OA 13038 A OA13038 A OA 13038A
Authority
OA
OAPI
Prior art keywords
pyridin
benzo
octahydro
pyrido
isoxazol
Prior art date
Application number
OA1200500259A
Other languages
English (en)
Inventor
Gene Michael Bright
Michael Aaron Brodney
Bishop Wlodecki
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA13038A publication Critical patent/OA13038A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
OA1200500259A 2003-03-12 2004-02-23 Pryridyloxymethyl and benzisoxazole azabicyclic derivatives. OA13038A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45392503P 2003-03-12 2003-03-12

Publications (1)

Publication Number Publication Date
OA13038A true OA13038A (en) 2006-11-10

Family

ID=32990837

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200500259A OA13038A (en) 2003-03-12 2004-02-23 Pryridyloxymethyl and benzisoxazole azabicyclic derivatives.

Country Status (31)

Country Link
US (1) US7345038B2 (fr)
EP (1) EP1608648B1 (fr)
JP (2) JP3910627B2 (fr)
KR (2) KR100767854B1 (fr)
CN (1) CN100389115C (fr)
AP (1) AP2005003390A0 (fr)
AR (1) AR043537A1 (fr)
AU (2) AU2004220327B2 (fr)
BR (1) BRPI0408248A (fr)
CA (1) CA2518740C (fr)
EA (1) EA009527B1 (fr)
EC (1) ECSP056011A (fr)
GT (1) GT200400041A (fr)
HK (1) HK1085725A1 (fr)
HR (1) HRP20050798A2 (fr)
IL (1) IL170290A (fr)
MA (1) MA27747A1 (fr)
MX (1) MXPA05009660A (fr)
NL (1) NL1025710C2 (fr)
NO (1) NO20054095L (fr)
OA (1) OA13038A (fr)
PA (1) PA8597501A1 (fr)
PE (1) PE20041057A1 (fr)
PL (1) PL378749A1 (fr)
RS (1) RS20050692A (fr)
TN (1) TNSN05224A1 (fr)
TW (1) TW200502234A (fr)
UA (1) UA78437C2 (fr)
UY (1) UY28225A1 (fr)
WO (1) WO2004081007A1 (fr)
ZA (1) ZA200506373B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994726B2 (en) * 2004-05-25 2006-02-07 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
AU2004282219C1 (en) 2003-10-15 2009-12-17 Osi Pharmaceuticals, Inc. Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
MXPA06008647A (es) * 2004-01-29 2006-09-04 Pfizer Prod Inc Combinaciones de un antipsicotico atipico y derivados azabiciclicos aminometilpiridiloximetil/bencisoxazol para tratar trastornos del sistema nervioso central.
RU2379308C2 (ru) * 2004-04-02 2010-01-20 Оси Фармасьютикалз, Инк. 6, 6-бициклические кольцевые замещенные гетеробициклические ингибиторы протеинкиназ
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
JP2008512441A (ja) * 2004-09-10 2008-04-24 ファイザー・プロダクツ・インク ピリジルオキシメチル、及びベンズイソオキサゾール・アザビシクロ誘導体を使用する、認知障害の治療方法
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
US20110046144A1 (en) * 2008-01-18 2011-02-24 Mulvihill Mark J Imidazopyrazinol derivatives for the treatment of cancers
WO2009143051A1 (fr) * 2008-05-19 2009-11-26 Osi Pharmaceuticals, Inc. Imidazopyrazines et imidazotriazines substituées
BRPI1016245A2 (pt) 2009-04-20 2015-09-01 Osi Pharmaceuticals Llc Preparação de c-pirazina-metilaminas.
EP2427192A1 (fr) * 2009-05-07 2012-03-14 OSI Pharmaceuticals, LLC Utilisation d'osi-906 dans le traitement du carcinome adrénocortical
US9394290B2 (en) * 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
CA2891122C (fr) 2012-11-14 2021-07-20 The Johns Hopkins University Methodes et compositions pour le traitement de la schizophrenie
WO2016115282A1 (fr) * 2015-01-13 2016-07-21 Vanderbilt University Composés à substituants benzisoxazole en tant que potentialisateurs allostériques de mglur4, compositions, et méthodes de traitement de dysfonctionnements neurologiques
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2020183011A1 (fr) 2019-03-14 2020-09-17 Institut Curie Inhibiteurs de htr1d et leurs utilisations dans le traitement du cancer
EP4429465A1 (fr) 2021-11-10 2024-09-18 Symrise AG Compositions comprenant des agents de refroidissement agonistes de trpm8

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008148A1 (fr) * 1989-01-23 1990-07-26 Pfizer Inc. Agents anxiolytiques bis-aza-bicycliques
US5167034A (en) * 1990-06-18 1992-11-24 International Business Machines Corporation Data integrity for compaction devices
US5157034A (en) 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
HUT71488A (en) * 1991-09-25 1995-11-28 Pfizer Process for the production of neuroleptic 2-substituted perhydro-1-h-pyrido[1,2a]pyrazines and pharmaceuticals compositions containing the same
US5719286A (en) * 1992-06-16 1998-02-17 Pfizer Inc. Process and intermediates for bis-aza-bicyclic anxiolytic agents
WO1996010570A1 (fr) * 1994-09-30 1996-04-11 Pfizer Inc. PERHYDRO-1H-PYRIDO[1,2-a] PYRAZINES DISUBSTITUEES EN 2,7 A ACTION NEUROLEPTIQUE
CN1157392C (zh) 1997-05-30 2004-07-14 神经研究公司 在尼古丁ach受体上作为胆碱能配体的8-氮杂双环(3,2,1)辛-2-烯以及辛烷衍生物
PA8469101A1 (es) * 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1
NZ509781A (en) 1998-08-26 2003-05-30 Aventis Pharma Ltd Quinoline or indolyl derivativees useful for modulating the inhibition of cell adhesion
PL346700A1 (en) 1998-09-18 2002-02-25 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors
ES2253930T3 (es) 1998-09-18 2006-06-01 ABBOTT GMBH & CO. KG 4-aminopirrolopirimidinas como inhibidores de quinasa.
UA62015C2 (en) * 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
ID30176A (id) 1999-03-12 2001-11-08 Boehringer Ingelheim Pharma Senyawa-senyawa yang bermanfaat sebagai zat anti-inflamasi
EP1177792A3 (fr) * 2000-07-27 2002-10-23 Pfizer Products Inc. Ligands dopamine d4 destines au traitement des troubles associees a la cherche de la nouveaute

Also Published As

Publication number Publication date
HK1085725A1 (en) 2006-09-01
UA78437C2 (en) 2007-03-15
MXPA05009660A (es) 2005-10-20
MA27747A1 (fr) 2006-02-01
EA009527B1 (ru) 2008-02-28
HRP20050798A2 (en) 2006-02-28
EP1608648B1 (fr) 2012-07-18
JP3910627B2 (ja) 2007-04-25
JP2006519830A (ja) 2006-08-31
PE20041057A1 (es) 2005-01-22
BRPI0408248A (pt) 2006-03-01
KR100767854B1 (ko) 2007-10-17
EP1608648A1 (fr) 2005-12-28
WO2004081007A1 (fr) 2004-09-23
TNSN05224A1 (fr) 2007-06-11
AU2010203303A1 (en) 2010-08-12
PA8597501A1 (es) 2005-05-24
TW200502234A (en) 2005-01-16
PL378749A1 (pl) 2006-05-15
NL1025710C2 (nl) 2005-10-10
AP2005003390A0 (en) 2005-09-30
RS20050692A (en) 2007-11-15
US20050026922A1 (en) 2005-02-03
CN1759116A (zh) 2006-04-12
NO20054095D0 (no) 2005-09-02
KR20050113221A (ko) 2005-12-01
CA2518740C (fr) 2011-01-11
US7345038B2 (en) 2008-03-18
AU2004220327A1 (en) 2004-09-23
NO20054095L (no) 2005-09-26
AU2004220327B2 (en) 2010-06-24
CN100389115C (zh) 2008-05-21
UY28225A1 (es) 2004-11-08
EA200501148A1 (ru) 2006-04-28
JP2007051155A (ja) 2007-03-01
AR043537A1 (es) 2005-08-03
ECSP056011A (es) 2006-01-27
IL170290A (en) 2011-02-28
NL1025710A1 (nl) 2004-09-14
GT200400041A (es) 2005-03-23
CA2518740A1 (fr) 2004-09-23
ZA200506373B (en) 2006-10-25
KR20070074667A (ko) 2007-07-12

Similar Documents

Publication Publication Date Title
IL170290A (en) Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
CA3033752C (fr) Derives d'aminoisoquinoleine substitues en position 4
CN112513036B (zh) 用作泛素特异性肽酶30抑制剂的稠合双环化合物
JP7438148B2 (ja) 心臓サルコメア阻害剤
TW200829243A (en) Azaadamantane derivatives and methods of use
TW201908293A (zh) 作為rock抑制劑之5員及雙環雜環醯胺
JP2015516957A (ja) 横隔膜機能を向上させるための方法
BR112014023460B1 (pt) Composto, formulação farmacêutica, uso de um composto
WO2007072017A2 (fr) Inhibiteurs d'enzymes
WO2023028564A1 (fr) Inhibiteurs spiro-indoliniques de la kif18a
WO2011149963A1 (fr) 6-méthylnicotinamides substitués utiles en tant que modulateurs allostériques positifs de mglur5
EA003400B1 (ru) Азабициклические лиганды рецепторов 5нт1
CN118103352A (zh) Kif18a的螺吲哚啉抑制剂
AU2021266743A1 (en) NAMPT modulators
JP2024501233A (ja) Ｎａｍｐｔモジュレーターとして有用なピラゾール誘導体
WO2024137981A1 (fr) Modulateurs de nampt